Antibacterial and mechanism of action studies of boxazomycin A.

Autor: Singh SB; Merck & Co. Inc., Rahway, NJ, 07065, USA. sbsingh101@gmail.com.; Charles A Dana Research Institute of Scientist Emeriti, Drew University, Madison, NJ, 07054, USA. sbsingh101@gmail.com.; Department of chemistry & Chemical Biology, Stevens Institute of Technology, Hoboken, NJ, 07030, USA. sbsingh101@gmail.com., Occi J; Merck & Co. Inc., Rahway, NJ, 07065, USA.; Center for Vector Biology, Rutgers University, New Brunswick, NJ, 08901, USA., Ondeyka J; Merck & Co. Inc., Rahway, NJ, 07065, USA., Barrett JF; Merck & Co. Inc., Rahway, NJ, 07065, USA., Masurekar P; Merck & Co. Inc., Rahway, NJ, 07065, USA., Motyl M; Merck & Co. Inc., Rahway, NJ, 07065, USA., Gill C; Merck & Co. Inc., Rahway, NJ, 07065, USA., Salituro G; Merck & Co. Inc., Rahway, NJ, 07065, USA.
Jazyk: angličtina
Zdroj: The Journal of antibiotics [J Antibiot (Tokyo)] 2024 Oct; Vol. 77 (10), pp. 679-684. Date of Electronic Publication: 2024 Aug 01.
DOI: 10.1038/s41429-024-00757-9
Abstrakt: Boxazomycins A-C are potent broad-spectrum antibiotics isolated from Actinomycetes strain G495-1 in 1987. We now report that boxazomycin A inhibits bacterial growth by selectively inhibiting protein synthesis, its effect is bacteriostatic, and it is equally active against drug resistant bacterial strains. No cross-resistance to protein synthesis inhibitors was observed suggesting that its inhibition is distinct from clinical protein synthesis inhibitors. We also report in vivo efficacy in a Staphylococcus aureus murine infection model supported by corresponding pharmacokinetic studies.
(© 2024. Merck & Co., Inc., Rahway, NJ, USA and its affiliates, under exclusive licence to the Japan Antibiotics Research Association.)
Databáze: MEDLINE
Externí odkaz: